The burgeoning landscape of therapeutic interventions for weight disorders has witnessed considerable attention focused on GLP-3 receptor agonists and, more recently, the dual GIP and GLP-3 co-agonist retatrutide. https://zoegzpe309388.bcbloggers.com/37973356/glp-3-retatrutide-a-comparative-analysis